Skip To Main Content
Brielle Benyon on Muck Rack

Brielle Benyon

Verified
New Jersey
As seen in: CURE Magazine, NJ.com, The Philadelphia Inquirer, NewsBreak, ONCOLOGY journal, OncLive, Contemporary OB/GYN, Dermatology Times, Drug Topics, Targeted Oncology, Urology Times and
Assistant managing editor at @CURE_today (curetoday.com) CrossFit L2 Mom to the coolest kid around
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Brielle

Contact Brielle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Nurses Can Help ‘Demystify’ Genetic Testing Results

|
By Brielle Benyon Verified
| Oncology Nursing News Verified
Genetic testing results can have numerous implications in cancer care—from targeted treatment regimens to the need for family members to get tested. Oncology nurses are in a prime position to help guide patients through the process, according to Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC. Sabo-Wagner is the vice president of Clinical Innovation for American Oncology Network.
Open in Who Shared Issue with article?

Rapid Taper Plays Role in Suspected Opioid Misuse in Patients With Cancer

|
By Brielle Benyon Verified
| Oncology Nursing News Verified
Tapering treatment with opioids for cancer-related pain can be a challenging process. However, when there is suspected opioid misuse, clinicians should consider faster tapering combined with non-opioid treatments to prevent harm to the patient or others, explained Heather J. Jackson, PhD, APRN, FNP-BC, NEA-BC, FAANP.
Open in Who Shared Issue with article?

Bispecific Antibodies Are ‘Not Your Typical Chemotherapy’ in Myeloma Treatment

|
By Brielle Benyon Verified
| Oncology Nursing News Verified
The use of bispecific antibodies have brought landmark change for the treatment of relapsed/refractory multiple myeloma, and tend to be well-tolerated, explained Carrie Lechtenberger, APRN, FNP-C, CCM, OCN, CBCN. “[Bispecific antibodies] are exciting. What they do is great, and I think patients overall have pretty tolerable, if any, side effects,” Lechtenberger, a family nurse practitioner at Levine Cancer Institute, Atrium Health, said.
Open in Who Shared Issue with article?
See all 1,040 licensed articles (2,268 Total)